← Back to Search
Metformin And Ovarian Cancer: The Evidence
E. Urpilainen, U. Puistola, S. Boussios, P. Karihtala
Published 2020 · Medicine
Download PDFAnalyze on Scholarcy
In recent decades, great interest in the off-label use of metformin has arisen as a result of its broad effects on different signaling pathways, with only a few side effects, and low cost. Metformin has been shown to have multiple, dose-dependent preclinical anticancer effects, which can be roughly divided into either direct effects via inhibition of mitochondrial respiratory chain complex I, or indirect effects through lowered glucose, insulin and insulin-like growth factor levels. Further details on in vitro and in vivo anticancer effects specifically in ovarian cancer are continuously reported. Preclinically metformin has clear chemosensitizing effects in ovarian cancer and it is an effective negative regulator of angiogenesis. There are also some epidemiological studies on metformin use in ovarian cancer, but the results of these studies are not as promising as those preclinical studies would indicate. Most preclinical studies have involved metformin concentrations that are many times higher than the pharmacological doses used in patients, which might confound the clinical use of metformin as regards the above-mentioned aspects. In this review we evaluate preclinical and clinical evidence concerning metformin in ovarian cancer treatment.
This paper references
Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus
C. Tseng (2015)
Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
F. Ricci (2019)
Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial
Y. Zheng (2019)
Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression
Rafaela Erices (2017)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
A. Ahmed (2010)
[Effect of phenformin on mammary gland tumor induction in rats].
Vladimir Dilman (1974)
Metformin and epithelial ovarian cancer therapeutics
Seema Patel (2015)
Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells.
Aniketh Bishnu (2019)
Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Isabella Dos Santos Guimarães (2018)
Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study
E. Urpilainen (2018)
Understanding the benefit of metformin use in cancer treatment
Ryan J O Dowling (2011)
Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.
A. Yasmeen (2011)
Molecular targets of metformin antitumor action.
Stanisław Sośnicki (2016)
Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanide (NNDG)
J. Sterne (1957)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
N. Colombo (2019)
Metformin and neoplasia: implications and indications.
A. Aljada (2012)
Diabetes mellitus and ovarian cancer: more complex than just increasing risk.
M. Shah (2014)
Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents
Chen Yang (2019)
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
M. Khawaja (2016)
Real-time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin
Yingzhao Liu (2018)
Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity
R. Romero (2017)
Metformin in combination with cisplatin inhibits cell viability and induces apoptosis of human ovarian cancer cells by inactivating ERK 1/2.
Jian-Hong Dang (2017)
The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case–control study
E. Urpilainen (2018)
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
Hsiao-Ping Chen (2012)
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4
Z. Škrott (2017)
Metformin intake is associated with better survival in ovarian cancer
S Kumar (2013)
Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
N. Kim (2015)
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
P. Home (2010)
Role of p53 Family Proteins in Metformin Anti-Cancer Activities
Y. Yi (2019)
Metformin in cancer treatment and prevention.
Daniel R. Morales (2015)
Metformin in 2019.
J. Flory (2019)
Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells.
Seema Patel (2015)
Inhibitory effect and mechanism of metformin on human ovarian cancer cells SKOV-3 and A2780.
J. Huo (2017)
Effect of metformin on the proliferation, apoptosis, invasion and autophagy of ovarian cancer cells
Ge Zou (2019)
Establishment of a Database of Metformin Plasma Concentrations and Erythrocyte Levels in Normal and Emergency Situations
Jean-Daniel Lalau (2011)
Metformin targets ovarian cancer stem cells in vitro and in vivo.
J. Shank (2012)
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?
N. Chandel (2016)
Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer
Shan-Bing Wang (2017)
Metformin inhibits ovarian cancer growth and migration in vitro and in vivo by enhancing cisplatin cytotoxicity.
Y. Zheng (2018)
Anticancer activity of metformin: a systematic review of the literature
M. Aljofan (2019)
Metformin and epithelial ovarian cancer
S Patel (2015)
A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
C. Garcia (2017)
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
W. Gotlieb (2008)
Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer
Chae Young Han (2019)
Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways
L. Ma (2019)
Metformin, at Concentrations Corresponding to the Treatment of Diabetes, Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer Cells
Rafaela Erices (2013)
Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway.
Y-L Fu (2017)
Inhibitory effects of metformin at low concentration on epithelial–mesenchymal transition of CD44+CD117+ ovarian cancer stem cells
R. Zhang (2015)
STUDIES IN THE METABOLISM CHANGES INDUCED BY ADMINISTRATION OF GUANIDINE BASES I. INFLUENCE OF INJECTED GUANIDINE HYDROCHLORIDE UPON BLOOD SUGAR CONTENT
C. Watanabe (1918)
Metformin and reduced risk of cancer in diabetic patients
J. Evans (2005)
Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity
Iris L Romero (2012)
The insulin and insulin-like growth factor receptor family in neoplasia: an update
M. Pollak (2012)
Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway.
H. Liao (2012)
The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer.
D. Bar (2016)
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W. Mcguire (1996)
Current state and outlook for drug repositioning anticipated in the field of ovarian cancer
Y. Kobayashi (2019)
Enhanced anti-proliferative and pro-apoptotic effects of metformin encapsulated PLGA-PEG nanoparticles on SKOV3 human ovarian carcinoma cells
Leila Faramarzi (2019)
Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
D. M. Baur (2011)
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
A. Gadducci (2016)
at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells
R Erices (2013)
Metformin inhibits the development and metastasis of ovarian cancer.
Buchu Wu (2012)
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis
X. Qiu (2017)
Use of metformin and the risk of ovarian cancer: a case-control analysis.
M. Bodmer (2011)
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
E. Lengyel (2015)
Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
F. Zhang (2018)
Cellular and molecular mechanisms of metformin: an overview.
B. Viollet (2012)